Loading company…
PROTIA develops and sells in vitro diagnostic kits and devices for allergies, pregnancy, cancer, and infectious diseases.
Founded in 2000 and based in Seoul, South Korea, PROTIA, formerly ProteomeTech, develops diagnostic kits and devices. Its products include allergy, cancer, immunity monitoring, pregnancy, and COVID-19 tests, as well as sample processing equipment. In June 2023, it raised KRW 7.2 billion in an IPO, selling 1.6 million shares at KRW 4,500 per share on KOSDAQ, where it trades under ticker 303360.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in